Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Lb Pharmaceuticals Inc (LBRX)

$30.52 +2.24 (7.92%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	875.16M
Revenue (ttm)	0.00
Net Income (ttm)	-25.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	341,500
Avg Vol	275,524
Day's Range	N/A - N/A
Shares Out	28.68M
Stochastic %K	97%
Beta	N/A
Analysts	Strong Sell
Price Target	$45.75

Company Profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 605 0300

Website: lbpharma.us

Address:

One Pennsylvania Plaza, Suite 1025, New York, United States

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

Mar 27, 2026, 12:00 PM EDT - 22 days ago

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 26, 2026, 4:05 PM EDT - 23 days ago

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Lb Pharmaceuticals Inc (LBRX)

Company Profile

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

LB Pharmaceuticals to Participate in Upcoming March Investor Events

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

LB Pharma valued at $382 million as shares jump in New York debut

LB Pharmaceuticals raises $285 million in US IPO

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

Neuropsychiatry biotech LB Pharmaceuticals files for a $100 million IPO

LB Pharmaceuticals IPO Registration Document (S-1)